AbbVie turned to Capsida Biotherapeutics two years ago for help delivering gene therapies into the brain. That partnership is ongoing, but the pharmaceutical giant now wants to leverage its partner’s technology for delivery of…
Continue Reading
Moderna’s ambitions in messenger RNA technology include therapies that do their editing work inside the patient. To that end, the biotech company is starting an R&D collaboration with a division of ElevateBio that brings…
Continue Reading
Healthcare has evolved significantly over the past decade. The widespread adoption of connected devices and cloud services has changed the way care is delivered and improved patient outcomes. These changes have been accompanied by…
Continue Reading
Clotting disorders can be treated by infusing patients with clotting proteins they lack, or with drugs that replace the function of these proteins. Gene therapies may soon become another option. Hemophilia A and B…
Continue Reading
The following is a guest article by Chris Menier, President of VIA AIOPS at Vitria Technology.
For healthcare providers and payers, improving the experience of members and patients requires replacing disconnected legacy systems with agile…
The COVID-19 pandemic accelerated digital transformation within healthcare, becoming a strategic part of improving care.As a preview of his HIMSS23 presentation, Dr. Jong Soo Choi, information technology lead at Samsung Medical Center, discussed SMC’s embedded technology with MobiHealthNews via email.
MobiHealthNews: How has Samsung Medical Center shifted its technology use over time?
Dr. Jong…
The National Institute of Standards and Technology says it will publish the Ascon group of algorithms in its lightweight cryptography standard later this year.WHY IT MATTERS
NIST has found “a worthy defender” of data generated by small Internet of Things-connected devices as the result of a four-year international competition, according to the…
Indian biotech company Mylab Discovery Solutions is integrating Qure.ai’s AI technology into its upcoming x-ray device for screening tuberculosis.According to a press statement, MyBeam is a compact, lightweight device equipped with high-frequency technology for detecting TB. It will be powered by Qure.ai’s deep-learning software qXR to analyse chest x-ray images and identify TB within a minute.
WHY IT MATTERS
India is one of the biggest contributors to global TB cases, accounting for 26% of the total global count and 34% of all TB deaths.
By leveraging technological innovation, both Mylab and Qure.ai aim to support the Indian government’s goal of eliminating TB by 2025. Their integrated…
Grifols, a company that turns blood plasma into therapies for immunological disorders and other conditions, is laying off about 2,000 U.S. workers as part of a corporate restructuring projected to yield up to €400 million in annual cost savings, the biotech announced Wednesday.
The layoffs represent about 8% of the Barcelona-based company’s global workforce, but they will happen mainly in its U.S. plasma operations. That’s notable because as a company that relies on plasma, the U.S. is vital to its business. The starting point for Grifols’s therapies is blood plasma. Key to its drug-making process is fractionation, in which the protein components…
A slew of biotech companies are pursuing research that could overcome limitations of current cell therapies. Startup creator Replay has a new subsidiary pushing toward the front of the pack with a therapeutic candidate on track to start its first human test this summer—about one year after Replay emerged from stealth. It owes this rapid progress to a cell therapy pioneer’s technology that has already been de-risked by a big pharmaceutical company.
Replay calls itself a genome writing company. With operations split between San Diego and London, the private equity-backed business launched last July with $55 million and a suite of technologies…
